SPOTLIGHT: J&J's risky infringement defense flops


Here's a new infringement-suit tactic: say your product isn't as safe as your opponent's, so it falls outside the patent's safety profile. That's what Johnson & Johnson said in its defense against Boston Scientific claims of stent-related poaching. It didn't work. The judge said that the infringement ruling stands. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.